Breaking News

Financial Report: AMRI

February 17, 2016

Contract revenue up 52% in the quarter

AMRI
 
4Q Revenues: $126.4 million (+46%)
 
4Q Earnings: $1.8 million (loss of $1.9 million 4Q14)
 
FY Revenues: $402.3 million (+45%)
 
FY Loss:
$2.3 million (loss of $3.3 million FY14)
 
Comments: Contract revenue for the quarter was $123.0 million, up 52%. Margins benefited from recent acquisitions, product mix within the Drug Product segment and the impact of cost reduction initiatives and facility optimization activities. Royalty revenue in the quarter was $3.4 million, down 43% due to lower royalties on Allegra products, which have ended based on the patent expirations.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks